Re-Rechallenge 177 Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer : A Step Further.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 39773689.
- Also identified by DOI 10.1097/RLU.0000000000005589.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
177 Lu-PSMA-617 radioligand therapy has been US Food and Drug Administration-approved safe and effective treatment modality for metastatic castration-resistant prostate cancer, usually administered in 4 to 6 cycles at 6 to 8 weeks apart. Many patients achieve partial response or stable disease with biochemical response after treatment. However, these effects are usually short-lived, and patients ultimately show disease progression after a median period of 6 to 9 months. Rechallenge therapy appears to be safe and effective treatment modality in such patients. We show the clinical efficacy and safety of re-rechallenge 177 Lu-PSMA radioligand therapy in a 64-year-old man with metastatic castration-resistant prostate cancer with disease progression on multiple lines of hormonal and chemotherapy treatment.
Medical subject headings
- Prostatic Neoplasms, Castration-Resistant
- Heterocyclic Compounds, 1-Ring
- Dipeptides
- Lutetium